60992-98-5

Basic information

• Product Name: 4'-Fluorobiphenyl-4-carbaldehyde
• Synonyms: TIMTEC-BB SBB010212;[1,1'-BIPHENYL]-4-CARBOXALDEHYDE, 4'-FLUORO-;4-(4-FLUOROPHENYL)BENZALDEHYDE;4'-FLUOROBIPHENYL-4-CARBALDEHYDE;4'-FLUORO[1,1'-BIPHENYL]-4-CARBALDEHYDE;4'-FLUORO-[1,1'-BIPHENYL]-4-CARBOXALDEHYDE;AKOS BAR-0061;ASINEX-REAG BAS 05891791
• CAS NO: 60992-98-5
• Molecular Formula: C₁₃H₉FO
• Molecular Weight: 200.21
• Product Categories: Aromatics;Intermediates;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 60992-98-5.mol
• Article Data: 42

Chemical Properties

• Melting Point: 93-97℃
• Boiling Point: 324℃
• Flash Point: >110°(230°F)
• Appearance: /
• Density: 1.173±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Sensitive: Air Sensitive
• CAS DataBase Reference: 4'-Fluorobiphenyl-4-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-Fluorobiphenyl-4-carbaldehyde(60992-98-5)
• EPA Substance Registry System: 4'-Fluorobiphenyl-4-carbaldehyde(60992-98-5)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-51-22
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 60992-98-5(Hazardous Substances Data)

Usage

Description

4'-Fluorobiphenyl-4-carbaldehyde is an organic compound with the molecular formula C13H9FO. It is characterized by its aromatic structure, featuring a biphenyl core with a fluorine atom at the 4' position and a formyl group (-CHO) at the 4 position. 4'-Fluorobiphenyl-4-carbaldehyde is known for its chemical reactivity and is often utilized as an intermediate in the synthesis of various pharmaceuticals and organic compounds.

Uses

Used in Pharmaceutical Industry:
4'-Fluorobiphenyl-4-carbaldehyde is used as an intermediate for the synthesis of Paroxetine, a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for the treatment of depression, anxiety, and other mood disorders. Its unique structure allows for the development of Paroxetine-related compounds with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic chemistry, 4'-Fluorobiphenyl-4-carbaldehyde serves as a valuable building block for the creation of more complex molecules. Its reactivity and functional groups make it a versatile compound for use in the synthesis of various organic compounds, including those with potential applications in materials science, pharmaceuticals, and other industries.
Chemical Properties:
The chemical properties of 4'-Fluorobiphenyl-4-carbaldehyde are not provided in the materials. However, based on its structure, it can be inferred that the compound may exhibit reactivity typical of aromatic compounds, such as electrophilic substitution and nucleophilic addition reactions. The presence of the fluorine atom and the formyl group may also influence its reactivity and the types of reactions it can undergo.

Upstream product

• 176913-70-5 bis(4-fluorophenyl)(hydroxy)borane 
• 1122-91-4 4-bromo-benzaldehyde 
• 128376-64-7 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 1765-93-1 4-fluoroboronic acid 
• 1643-96-5 7-(4-fluorophenyl)cyclohepta-1,3,5-triene 
• 15164-44-0 p-(iodophenyl)carboxaldehyde 
• 87199-17-5 4-formylphenylboronic acid, 
• 42030-76-2 4-((4,6-dimethoxy-1,3,5-triazin-2-yl)oxy)benzaldehyde 
• 123-08-0 4-hydroxy-benzaldehyde 
• 398-21-0 4-bromo-4'-fluorobiphenyl 
• 598-30-1 sec.-butyllithium 
• 189254-48-6 (C₆H₄F)2BOCH(CH₃)2 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 1238219-09-4 C₃₅H₂₇FN₂O 
• 1401624-51-8 N'-((4'-fluorobiphenyl-4-yl)methyl)sulfonyl hydrazide 
• 1401624-52-9 C₂₂H₂₄FNO₄ 
• 1401624-53-0 (1R,2R)-methyl 1-amino-2-(4-fluorobipheny-4-yl)cyclopropanecarboxylate 
• 1401624-54-1 (1R,2R)-methyl 1-((S)-2-(tert-butoxycarbonylamino)butanamido)-2-(4'-fluorobiphenyl-4-yl)cyclopropanecarboxylate 
• 1401624-55-2 tert-butyl (S)-1-((1R,2R)-1-carbamoyl-2-(4'-fluorobiphenyl-4-yl)cyclopropylamino)-1-oxobutan-2-ylcarbamate 
• 1401624-57-4 tert-butyl (S)-1-((1R,2R)-1-cyano-2-(4'-fluorobiphenyl-4-yl)cyclopropylamino)-1-oxobutan-2-ylcarbamate 
• 1401624-20-1 (S)-2-amino-N-((1R,2R)-1-cyano-2-(4'-fluorobiphenyl-4-yl)cyclopropyl)butanamide 
• 1622397-93-6 (E)-3-(4'-fluoro-4-biphenylyl)-1-(2-hydroxy-4-methoxyphenyl)2-propen-1-one 
• 1630951-38-0 7-(1-((4'-fluorobiphenyl-4-yl)methyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one 
• 1630951-32-4 7-(4-((4'-fluorobiphenyl-4-yl)methyl)piperazin-1-yl)-3,4-dihydroquinazolin-2(1H)-one 
• 1627741-50-7 6-{4-[(4'-fluorobiphenyl-4-yl)methyl]piperazin-1-yl}-3,4-dihydroquinazolin-2(1H)-one 
• 1581275-07-1 5-(1-((4'-Fluorobiphenyl-4-yl)methyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one 
• 1581275-13-9 5-(4-((4'-fluorobiphenyl-4-yl)methyl)piperazin-1-yl)-1H-benzo[d]imidazol-2(3H)-one 

Relevant articles and documents

Desleucyl-Oritavancin with a Damaged d -Ala- d -Ala Binding Site Inhibits the Transpeptidation Step of Cell-Wall Biosynthesis in Whole Cells of Staphylococcus aureus

We have used solid-state nuclear magnetic resonance to characterize the exact nature of the dual mode of action of oritavancin in preventing cell-wall assembly in Staphylococcus aureus. Measurements performed on whole cells labeled selectively in vivo have established that des-N-methylleucyl-N-4-(4-fluorophenyl)benzyl-chloroeremomycin, an Edman degradation product of [19F]oritavancin, which has a damaged d-Ala-d-Ala binding aglycon, is a potent inhibitor of the transpeptidase activity of cell-wall biosynthesis. The desleucyl drug binds to partially cross-linked peptidoglycan by a cleft formed between the drug aglycon and its biphenyl hydrophobic side chain. This type of binding site is present in other oritavancin-like glycopeptides, which suggests that for these drugs a similar transpeptidase inhibition occurs.

Pd(II)-Mediated C?H Activation for Cysteine Bioconjugation

Selective bioconjugation remains a significant challenge for the synthetic chemist due to the stringent reaction conditions required by biomolecules coupled with their high degree of functionality. The current trailblazer of transition-metal mediated bioconjugation chemistry involves the use of Pd(II) complexes prepared via an oxidative addition process. Herein, the preparation of Pd(II) complexes for cysteine bioconjugation via a facile C?H activation process is reported. These complexes show bioconjugation efficiency competitive with what is seen in the current literature, with a user-friendly synthesis, common Pd(II) sources, and a more cost-effective ligand. Furthermore, these complexes need not be isolated, and still achieve high conversion efficiency and selectivity of a model peptide. These complexes also demonstrate the ability to selectively arylate a single surface cysteine residue on a model protein substrate, further demonstrating their utility.

The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both in Vitro and in Vivo

The transient receptor potential melastatin 2 (TRPM2) channel is associated with ischemia/reperfusion injury, inflammation, cancer, and neurodegenerative diseases. However, the limit of specific inhibitors impedes the development of TRPM2-targeted therapeutic agents. To discover more potent and selective TRPM2 inhibitors, 59 N-(p-amylcinnamoyl) anthranilic acid (ACA) derivatives were synthesized and evaluated using calcium imaging and electrophysiology approaches. Systematic structure-activity relationship studies resulted in some potent compounds inhibiting the TRPM2 channel with sub-micromolar half-maximal inhibitory concentration values. Among them, the preferred compound A23 exhibited TRPM2 selectivity over TRPM8 and TRPV1 channels as well as phospholipase A2 and showed neuroprotective activity in vitro. Following pharmacokinetic studies, A23 was further evaluated in a transient middle cerebral artery occlusion model in vivo, which significantly reduced cerebral infarction. These data indicate that A23 might serve as a useful tool for TRPM2-related research as well as a lead compound for the development of therapeutic agents for ischemic injury.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS

The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular for the use in the treatment of diseases or disorders wherein disrupting Rad51-BRCA2 interaction is beneficial.